Biography
Dr Chatterton obtained both bachelors (Philadelphia College of Pharmacy and Science, 1984- 1989) and doctoral (Rutgers University, 1993-1995) degrees in Pharmacy. She completed a 2-year Pharmacoeconomic research training fellowship which focused on health economic and research methods (1995-1997). This led to research assessing the economic and clinical outcomes of medications from clinical trials as well as modelled evaluations for respiratory syncytial virus, HIV, and migraine. Dr Chatterton has worked in health economics in a variety of settings including pharmaceutical industry, academia and consulting. Her current work relates to the economic evaluation of medications and psychological interventions to prevent and treat mental health conditions including bipolar disorder, schizophrenia, anxiety and depression. She is responsible for the practical implementation and analysis of economic evaluations within a number of clinical trials as well as developing economic models to estimate the cost effectiveness of mental health interventions.
Read more on Mary Lou's profileResearch interests
My main interest lies in economic evaluation. My goal is to provide results on the value of medications and other interventions to allow policy makers, clinicians and patients to make informed decisions about cost effective care. My clinical pharmacy background has allowed me to work across a variety of areas including infectious diseases (HIV, hepatitis, respiratory syncytial virus), neurology (migraine, multiple sclerosis), and mental health (schizophrenia, bipolar disorder, anxiety). I have extensive experience and interest in conducting economic evaluations alongside clinical trials, as well as constructing decision analytic models for evaluating cost effectiveness.
Knowledge areas
Health Economics, Economic Evaluation, Patient reported outcome measurement (quality of life, satisfaction), Mental Health, Clinical Trials, Medications
Professional activities
In addition to Mary Lou’s responsibilities as a research fellow she also provides leadership through her appointment as Chair of the Deakin University Human Research Ethics Committee. She has served on the management committee of the Australian Chapter of the International Society for Pharmacoeconomics and Outcomes Research (2012 – 2015) and as a member of the organising committee for the 10th International Conference of the International Society on Priorities in Healthcare held in Melbourne in 2014.
Publications
M Chatterton, J Bayer, L Engel, R Rapee, R Beatson, H Hiscock, L Bretherton, M Wake, C Mihalopoulos
(2020), Vol. 70, pp. 1-9, Journal of Anxiety Disorders, Amsterdam, The Netherlands, C1
Low intensity treatment for clinically anxious youth: a randomised controlled comparison against face-to-face intervention
R Rapee, H Lyneham, V Wuthrich, M Chatterton, J Hudson, M Kangas, C Mihalopoulos
(2020), European Child and Adolescent Psychiatry, C1
Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean
(2019), Vol. 41, pp. 245-253, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1
Wang-Sheng Lee, Cathrine Mihalopoulos, Mary Chatterton, Georgina Chambers, Nicole Highet, Vera Morgan, Elizabeth Sullivan, Marie-Paule Austin
(2019), Vol. 46, pp. 277-287, Administration and policy in mental health and mental health services research, New York, N.Y., C1
Susan Fletcher, Patty Chondros, Victoria Palmer, Mary Chatterton, Matthew Spittal, Cathrine Mihalopoulos, Anna Wood, Meredith Harris, Philip Burgess, Bridget Bassilios, Jane Pirkis, Jane Gunn
(2019), Vol. 78, pp. 63-75, Contemporary clinical trials, Amsterdam, The Netherlands, C1
Mary Chatterton, Ronald Rapee, Max Catchpool, Heidi Lyneham, Viviana Wuthrich, Jennifer Hudson, Maria Kangas, Cathrine Mihalopoulos
(2019), Vol. 53, pp. 673-682, Australian and New Zealand journal of psychiatry, London, Eng., C1
The economic costs of loneliness: a review of cost-of-illness and economic evaluation studies
Cathrine Mihalopoulos, Long Le, Mary Chatterton, Jessica Bucholc, Julianne Holt-Lunstad, Michelle Lim, Lidia Engel
(2019), pp. 1-14, Social psychiatry and psychiatric epidemiology, Berlin, Germany, C1
J Firth, N Siddiqi, A Koyanagi, D Siskind, S Rosenbaum, C Galletly, S Allan, C Caneo, R Carney, A Carvalho, M Chatterton, C Correll, J Curtis, F Gaughran, A Heald, E Hoare, S Jackson, S Kisely, K Lovell, M Maj, P McGorry, C Mihalopoulos, H Myles, B O'Donoghue, T Pillinger, J Sarris, F Schuch, D Shiers, L Smith, M Solmi, S Suetani, J Taylor, S Teasdale, G Thornicroft, J Torous, T Usherwood, D Vancampfort, N Veronese, P Ward, A Yung, E Killackey, B Stubbs
(2019), Vol. 6, pp. 675-712, The Lancet psychiatry, Amsterdam, The Netherlands, C1
Long Le, Lena Sanci, Mary Chatterton, Sylvia Kauer, Kerrie Buhagiar, Cathrine Mihalopoulos
(2019), Vol. 21, pp. 1-12, Journal of medical internet research, Toronto, Ont., C1
J Stiles, M Chatterton, L Le, Y Lee, H Whiteford, C Mihalopoulos
(2019), Vol. 125, pp. 1-8, Journal of psychosomatic research, Amsterdam, The Netherlands, C1
Louise Birrell, Nicola Newton, Tim Slade, Catherine Chapman, Louise Mewton, Nyanda McBride, Leanne Hides, Mary Chatterton, Steve Allsop, Annalise Healy, Marius Mather, Catherine Quinn, Cathrine Mihalopoulos, Maree Teesson
(2019), Vol. 8, pp. 1-2, JMIR research protocols, Toronto, Ont., C1
Cathrine Mihalopoulos, Lidia Engel, Long Le, Anne Magnus, Meredith Harris, Mary Chatterton
(2018), Vol. 27, pp. 1815-1825, Quality of life research, Dordrecht, The Netherlands, C1
Economic evaluation of a dietary intervention for adults with major depression (the "SMILES" trial)
Mary Chatterton, Cathrine Mihalopoulos, Adrienne O'Neil, Catherine Itsiopoulos, Rachelle Opie, David Castle, Sarah Dash, Laima Brazionis, Michael Berk, Felice Jacka
(2018), Vol. 18, BMC public health, London, Eng., C1
G Chambers, S Randall, C Mihalopoulos, N Reilly, E Sullivan, N Highet, V Morgan, M Croft, M Chatterton, M Austin
(2018), Vol. 42, pp. 514-521, Australian health review, Clayton, Vic., C1
Louise Birrell, Nicola Newton, Tim Slade, Catherine Chapman, Louise Mewton, Nyanda McBride, Leanne Hides, Mary Chatterton, Steve Allsop, Annalise Healy, Marius Mather, Catherine Quinn, Cathrine Mihalopoulos, Maree Teesson
(2018), Vol. 7, pp. 1-13, JMIR research protocols, Toronto, Ont., C1
F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk
(2017), Vol. 15, pp. 1-13, BMC medicine, London, Eng., C1
M Chatterton, E Stockings, M Berk, J Barendregt, R Carter, C Mihalopoulos
(2017), Vol. 210, pp. 333-341, British journal of psychiatry, London, Eng., C1
Y-C Lee, M Chatterton, A Magnus, M Mohebbi, L Le, C Mihalopoulos
(2017), Vol. 51, pp. 1198-1211, Australian and New Zealand journal of psychiatry, London, Eng., C1
R Rapee, H Lyneham, V Wuthrich, M Chatterton, J Hudson, M Kangas, C Mihalopoulos
(2017), pp. 1-8, ABCT 2016 : Proceedings of the 50th Annual Conference of the Association for Behavioral and Cognitive Therapies, New York, New York, E1
M Chatterton, S Chambers, S Occhipinti, A Girgis, J Dunn, R Carter, S Shih, C Mihalopoulos
(2016), Vol. 25, pp. 857-864, Psycho-oncology, Chichester, Eng., C1
Economic evaluations of interventions designed to prevent mental disorders: a systematic review
C Mihalopoulos, M Chatterton
(2015), Vol. 9, pp. 85-95, Early intervention in psychiatry, London, Eng., C1
C Mihalopoulos, T Vos, R Rapee, J Pirkis, M Chatterton, Y Lee, R Carter
(2015), Vol. 56, pp. 1026-1033, Journal of child psychology and psychiatry, Chichester, Eng., C1
A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka
(2013), Vol. 13, BMC Psychiatry, C1
M Ekman, P Lindgren, C Miltenburger, G Meier, J Locklear, M Chatterton
(2012), Vol. 30, pp. 513-531, PharmacoEconomics, Dordrecht, The Netherlands, C1-1
E Vieta, O Günther, J Locklear, M Ekman, C Miltenburger, M Chatterton, M Åström, B Paulsson
(2011), Vol. 14, pp. 1029-1049, International Journal of Neuropsychopharmacology, C1-1
Treatment options for bipolar depression: A systematic review of randomized, controlled trials
E Vieta, J Locklear, O Günther, M Ekman, C Miltenburger, M Chatterton, M Åström, B Paulsson
(2010), Vol. 30, pp. 579-590, Journal of Clinical Psychopharmacology, C1-1
Impact of bipolar disorder on the family: Utilization and cost of health care resources
M Chatterton, X Ke, B Lewis, K Rajagopalan, A Lazarus
(2008), Vol. 33, P and T, C1-1
Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review
R Fleurence, M Chatterton, J Dixon, K Rajagopalan
(2007), Vol. 9, pp. 419-428, Primary care companion to the journal of clinical psychiatry, Memphis, TN, C1-1
The Family Impact and Costs of Migraine
P Stang, W Crown, R Bizier, M Chatterton, R White
(2004), Vol. 10, pp. 313-320, American Journal of Managed Care, C1-1
Reliability and validity of the Migraine Therapy Assessment Questionnaire
M Chatterton, J Lofland, A Shechter, W Curtice, X Hu, J Lenow, S Smullens, D Nash, S Silberstein
(2002), Vol. 42, pp. 1006-1015, Headache, Hoboken, N. J., C1-1
Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine
J Lofland, S Kim, A Batenhorst, N Johnson, M Chatterton, R Cady, R Kaniecki, D Nash
(2001), Vol. 76, pp. 1093-1101, Mayo Clinic proceedings, New York, N. Y., C1-1
J Lofland, S Touch, J O'Connor, M Chatterton, E Moxey, L Paddock, D Nash, S Desai
(2000), Vol. 22, pp. 1357-1369, Clinical therapeutics, Bridgewater, N. J., C1-1
L Paddock, J Veloski, M Chatterton, F Gevirtz, D Nash
(2000), Vol. 23, pp. 951-956, Diabetes care, Alexandria, VA, C1-1
M Chatterton, J Scott-Lennox, A Wu, J Scott
(1999), Vol. 15, pp. 67-74, PharmacoEconomics, Auckland, N. Z., C1-1
Funded Projects at Deakin
Australian Competitive Grants
Healthy, wealthy and wise: The long-term effectiveness of an online universal program to prevent substance use and mental health problems among Australian youth
Prof Maree Teesson, A/Prof Nuicola Newton, A/Prof Timothy Slade, Dr Catherine Chapman, Dr Louise Mewton, A/Prof Leanne Hides, Dr Nyanda McBride, Dr Mary Lou Chatterton, Ms Louise Birrell, Steve Allsop
NHMRC Project Grant
- 2020: $8,945
- 2019: $17,891
- 2018: $26,837
The Candesartan Adjunctive bipolar DEpression Trial - CADET
Prof Michael Berk, Prof Gin Malhi, A/Prof Chee Ng, Prof Malcolm Hopwood, Ms Brisa Simoes Fernandes, Dr Stella Gwini, Dr John Amerena, Dr Mary Lou Chatterton, Prof Trisha Suppes, A/Prof Lana Williams
MRFF Clinical Trials Activity: Rare Cancers, Rare Diseases and Unmet Need Grant
- 2020: $30,666
- 2019: $2,103,202
The Candesartan Adjunctive Major Depression Trial - CADET: A double-blind, randomised, placebo-controlled trial
Prof Michael Berk, Prof Gin Malhi, Prof Chee Ng, Prof Malcolm Hopwood, Ms Brisa Simoes Fernandes, Dr Stella Gwini, Dr John Amerena, Dr Mary Lou Chatterton, A/Prof Lana Williams
NHMRC - Clinical Trials and Cohort Studies Grant
- 2021: $4,603
- 2020: $201,835
Evaluating the effectiveness of lifestyle therapy versus standard psychotherapy for reducing depression in adults with COVID-19 related distress: The CALM trial
A/Prof Adrienne O'Neil, Prof Felice Jacka, Prof Jim Lagopoulos, Prof Murat Yucel, Prof Jane Speight, Dr Pilvikki Absetz, A/Prof Vincent Versace, Dr Megan Teychenne, Simon Rosenbaum, Dr Mary Lou Chatterton
MRFF COVID-19 Mental Health Research Grant
- 2020: $885,302
Other Public Sector Funding
Development of MyMAPS, an innovative blended face-to-face and mobile application psychosocial intervention for bipolar disorder
Prof Michael Berk, Dr Lesley Berk, Prof David Castle, Prof Malcolm Hopwood, Dr Mohammadreza Mohebbi, Prof Greg Murray, Prof John Grundy, Dr Mary Lou Chatterton, Dr Sue Lauder, Dr Emma Gliddon
- 2018: $99,872
Link-me (Primary Health Network Mental Health Reform Lead Site Project: Evaluation Part B) A randomised controlled trial of a systematic model of stepped mental health care in general.
Prof Cathy Mihalopoulos, Dr Mary Lou Chatterton
- 2020: $96,749
- 2019: $175,317
- 2018: $145,453
Industry and Other Funding
Cost of illness for high prevalence mental disorders in Australia
Prof Cathy Mihalopoulos, Dr Mary Lou Chatterton, Ms Yu-Chen Lee, Ms Anne Magnus, Dr Mohammadreza Mohebbi
- 2014: $50,000
The socio-economic benefits of early intervention services for vulnerable young people and their families in Geelong and surrounds
Dr Mary Lou Chatterton, Prof Cathy Mihalopoulos
- 2016: $39,900
Development of MyMAPS, an innovative blended face-to-face and mobile application psychosocial intervention for bipolar disorder
Prof Michael Berk, Dr Lesley Berk, Prof David Castle, Prof Malcolm Hopwood, Dr Mohammadreza Mohebbi, Prof Greg Murray, Prof John Grundy, Dr Mary Lou Chatterton, Dr Sue Lauder, Dr Emma Gliddon
- 2018: $100,000
Economic Evaluation of The Way Back Support Service (NSW)
Prof Cathy Mihalopoulos, Dr Mary Lou Chatterton, Mr Scott Richards - Jones
- 2019: $28,536
- 2017: $85,609
Supervisions
No completed student supervisions to report